Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Maruyama, Dai, Hatake, Kiyohiko, Kinoshita, Tomohiro, Fukuhara, Noriko, Choi, Ilseung, Taniwaki, Masafumi, Ando, Kiyoshi, Terui, Yasuhito, Higuchi, Yusuke, Onishi, Yasushi, Abe, Yasunobu, Kobayashi, Tsutomu, Shirasugi, Yukari, Tobinai, Kensei
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448600/
https://ncbi.nlm.nih.gov/pubmed/28267244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars